Whole-Blood Impedance Aggregometry for Diagnosing HIT Whole-Blood Impedance Aggregometry for Diagnosing HIT
Might whole-blood impedance aggregometry be a faster and simpler alternative to the gold-standard C-serotonin release assay for diagnosis of heparin-induced thrombocytopenia?American Journal of Clinical Pathology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 9, 2019 Category: Allergy & Immunology Tags: Pathology & Lab Medicine Journal Article Source Type: news
FDA Expands Indication for Platelet Booster Avatrombopag FDA Expands Indication for Platelet Booster Avatrombopag
Avatrombopag is now indicated for adults with thrombocytopenia and chronic immune thrombocytopenia; it is already approved for adults with thrombocytopenia and chronic liver disease.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
DURHAM, N.C., June 27, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news
Dova receives European marketing authorization
Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort.
The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease.
The company's stock was up almost 10 percent Wednesday following… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 25, 2019 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news
Dova receives European marketing authorization
Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort.
The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease.
The company's stock was up almost 10 percent Wednesday following… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 25, 2019 Category: American Health Authors: Seth Thomas Gulledge Source Type: news
Young Girl Afraid Of IVs Invents ‘ Medi Teddy ’ To Disguise Them
(CNN) — A young girl from Connecticut turned her time spent in the hospital into a chance to help ease the fear of many other young patients.
Ella Casano, now 12, was diagnosed with an autoimmune disease called Idiopathic Thrombocytopenia Purpura (ITP) when she was seven.
“It’s when her body attacks and destroys its own platelets, so it puts her at higher risk for bleeding or injury, more than most people,” Meg Casano, Ella’s mother, told CNN.
Due to ITP, Ella had to have IV infusions every six to eight weeks. As for many young children, and adults, this process scared her.
“When I had m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Source Type: news
An Assay for Screening of Heparin-Induced Thrombocytopenia An Assay for Screening of Heparin-Induced Thrombocytopenia
This study evaluated the usefulness of an alternative assay, the PIFA PLUSS P4, as a rapid screening test for the diagnosis of heparin-induced thrombocytopenia.Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 13, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news
What Clinical Symptoms Can An Infant with Polycythemia Have?
Discussion
Polycythemia is defined as a venous hematocrit of > 65% or a venous hemoglobin of > 22 g/dL. Capillary values are unreliable and any values greater than normal should be repeated with a venous sampling for confirmation. Hyperviscosity is distinct from polycythemia and “… is defined as a viscosity greater than 14.6 cP at a shear rate of 11.5 per second, or a value 2 standard deviations above the mean.” Hyperviscosity is difficult to measure in the clinical setting therefore polycythemia is often used as a proxy.
Polycythemia occurs in about ~1.5-5% of births. Risk factors for it includes...
Source: PediatricEducation.org - April 29, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
ITP and B-cell Lymphoma Feature in Latest BSH Guidance ITP and B-cell Lymphoma Feature in Latest BSH Guidance
Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Flash-Mob Audit Shows Ig Overused in Immune Thrombocytopenia Flash-Mob Audit Shows Ig Overused in Immune Thrombocytopenia
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes
Cytopenias are an important clinical problem associated with inflammatory disease and infection. We show that specialized phagocytes that internalize red blood cells develop in Toll-like receptor 7 (TLR7)–driven inflammation. TLR7 signaling caused the development of inflammatory hemophagocytes (iHPCs), which resemble splenic red pulp macrophages but are a distinct population derived from Ly6Chi monocytes. iHPCs were responsible for anemia and thrombocytopenia in TLR7-overexpressing mice, which have a macrophage activation syndrome (MAS)–like disease. Interferon regulatory factor 5 (IRF5), associated with MAS, p...
Source: ScienceNOW - January 10, 2019 Category: Science Authors: Akilesh, H. M., Buechler, M. B., Duggan, J. M., Hahn, W. O., Matta, B., Sun, X., Gessay, G., Whalen, E., Mason, M., Presnell, S. R., Elkon, K. B., Lacy-Hulbert, A., Barnes, B. J., Pepper, M., Hamerman, J. A. Tags: Immunology, Online Only r-articles Source Type: news
Amgen Submits Supplemental Biologics License Application For Nplate ® (romiplostim)
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less
THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy.
"Patients living with ITP need more flexibility in their treatment options, and we believe...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing
Two researchers hailed as ' Choosing Wisely Champions ' describe how they reduced blood transfusions and inappropriate testing for heparin-induced thrombocytopenia (HIT).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
